Inside a Scientific Advisory Board: How Expert Oversight Shapes CNS Drug Development
Walk into any biotech's pipeline page and you'll see the same things: a list of compounds, a few trial phases, maybe a chart showing progress toward approval.
What you won't see, unless you go looking, is the group of outside physicians and researchers quietly shaping almost every decision behind that pipeline.
That's the scientific advisory board, and in central nervous system (CNS) drug development, it's often the difference between a program that stalls in Phase 2 and one that makes it to an FDA submission.
For a company like Bright Minds Biosciences, working across drug-resistant epilepsy, Prader-Willi Syndrome, and neuropsychiatric disorders, a CNS drug development advisory board isn't a symbolic gesture.
It's a working group of specialists who've spent decades treating the exact patients the company is trying to help.
What Is a Scientific Advisory Board in Biotech?
A scientific advisory board (SAB) is a group of external experts, usually academic physicians, researchers, or former regulators, who advise a drug company on the science, clinical strategy, and real-world feasibility of its programs.
They aren't employees. They aren't on the payroll in the traditional sense either, though many hold equity or receive consulting fees. Their value comes from independence combined with deep, specific expertise that a small biotech team can't replicate in-house.
Think about what a CNS-focused company is up against. Neurological and psychiatric conditions are notoriously hard to treat because the brain doesn't give up its secrets easily, and patient populations are often small, heterogeneous, and difficult to recruit for trials.
An internal team of ten or twenty scientists, however talented, has limited firsthand experience running pediatric epilepsy trials, negotiating FDA labeling language, or recognizing which endpoints matter to patients versus which just look good on paper. That's where an SAB earns its keep.
Why Do Biotech Companies Need Outside Experts?
Because credibility in drug development isn't self-declared. Regulators, investors, and physicians all want to know that a company's science has been checked by people outside the building.
An SAB member with a professorship at Stanford or a directorship at Children's Hospital of Philadelphia brings a kind of validation that no press release can manufacture on its own.
There's also a practical dimension. Advisory board members often sit on the boards of other organizations, such as the Dravet Syndrome Foundation or the Epilepsy Study Consortium, giving them visibility into how trials are run across the industry.
That means they know which protocol designs tend to fail, which patient recruitment strategies work in rare disease populations, and which regulatory arguments have succeeded (or fallen flat) with the FDA in the past.
How Advisory Boards Shape Clinical Trial Design
This is where the abstract idea of "expert oversight" becomes concrete. Advisory board members typically weigh in on:
- Endpoint selection: deciding what to measure in a trial (seizure frequency, sleep quality, behavioral scores) so the data will hold up with regulators
- Patient population definition: helping define who qualifies for a trial, which matters enormously in rare epilepsy syndromes where diagnostic criteria can be inconsistent
- Dosing strategy: advising on titration schedules based on what's worked, or backfired, in related compounds
- Trial site selection: recommending centers with experience in a specific rare disease
- Regulatory strategy: helping interpret FDA feedback and shape the argument for a given indication
Bright Minds Biosciences offers a clear real-world example. When the company expanded its scientific advisory board in March 2025, it added five epilepsy specialists:
Dennis Dlugos of the University of Pennsylvania and Children's Hospital of Philadelphia, Jacqueline French of NYU Grossman School of Medicine, Terence O'Brien of Monash University, Jo Sourbron of University Hospitals Ghent, and Joseph Sullivan of UCSF.
That expansion happened specifically to support the Phase 2 BREAKTHROUGH study of BMB-101 in adult patients with absence epilepsy and developmental and epileptic encephalopathy (DEE).
This wasn't a cosmetic hire. Dr. Dlugos has coordinated FDA discussions around extrapolating efficacy data across age groups and around defining DEE as a clinical indication for pivotal trials.
Dr. French founded the Epilepsy Study Consortium and has authored over 300 papers on antiseizure medicine. Dr. Sourbron spent over a decade researching serotonergic compounds specifically for drug-resistant epilepsy, including prior clinical work with fenfluramine, a related 5-HT2 agonist.
That kind of background doesn't just add prestige to a company page. It directly informs how a trial like BREAKTHROUGH gets designed and interpreted.
What Happens When a Company Skips This Step?
Plenty of drug candidates have failed not because the underlying science was wrong, but because the trial around it was designed poorly.
A classic example in the broader CNS space is a trial that picks the wrong primary endpoint, one that doesn't reflect what clinicians or patients care about, and then technically "fails" even though the drug shows real benefit on other measures.
Advisory boards exist precisely to catch these mistakes before they become expensive, multi-year errors.
Comparing Internal R&D Teams vs. External Advisory Boards
Factor
Internal R&D Team
Scientific Advisory Board
Day-to-day control
Full control over daily execution
Advisory input at key decision points
Patient population experience
Varies by hires
Often decades of direct clinical exposure
Regulatory relationships
Company-specific
Frequently includes FDA interaction history
Independence
Employed by the company
External, adds credibility to claims
Cost structure
Salaries, benefits
Equity, consulting fees, honoraria
Best for
Execution, data management, operations
Strategic direction, trial design, credibility
Neither group replaces the other. A strong CNS drug developer needs both: an internal team that can execute day to day, and an advisory board that stress-tests the strategy from the outside.
Read: Pharmaceutical Software Solutions and Development
How Do Advisory Boards Build Trust With Regulators and Investors?
Trust in biotech is built in layers. A company can publish preclinical data showing a compound works in animal models, but that alone doesn't tell a regulator, or an investor, whether the human trial design makes sense. Named advisory board members change that calculus in a few specific ways:
- Peer validation: when a recognized epilepsy researcher publicly joins a company's SAB, it signals to peers in the field that the science has passed at least an informal gut check
- Track record transfer: a board member's history of successful FDA interactions (like discussions on DEE as a clinical indication) lends the company some of that same regulatory fluency
- Reduced information asymmetry: investors evaluating a clinical-stage biotech often can't assess the underlying neuroscience themselves, so they lean on the credentials of the people advising the company
This matters more in CNS than in almost any other therapeutic area. Cardiovascular or oncology endpoints are often more standardized.
Psychiatric and neurological endpoints are messier, more subjective, and more prone to disagreement among experts, which makes independent expert input especially valuable rather than optional.
Common Mistakes Companies Make With Advisory Boards
- Treating the SAB as a marketing asset only. Naming well-known physicians on a press release without giving them real input into trial design defeats the purpose and can backfire if regulators or journalists notice the disconnect.
- Building a board with overlapping expertise. Five neurologists with the same subspecialty won't catch the same blind spots that five people spanning epilepsy, psychiatry, and pharmacology would.
- Ignoring board feedback that contradicts internal assumptions. The whole value of an outside perspective disappears if leadership only listens when the advice confirms what they already believed.
- Failing to update the board as the pipeline evolves. A board assembled for an epilepsy program may need psychiatric or metabolic disease specialists added once a company expands into new indications, the way Bright Minds added expertise as its Prader-Willi Syndrome and neuropsychiatry programs matured.
How Bright Minds Biosciences Structures Scientific Oversight
Bright Minds' advisory board reflects a fairly deliberate build-out rather than a one-time announcement.
The original 2022 board brought together Herbert Meltzer of Northwestern University, Robert Malenka of Stanford, Michael Bogenschutz of NYU Langone Health, and Peter Hendricks of the University of Alabama, researchers with backgrounds spanning psychopharmacology, neuroscience, and addiction
medicine.
As the company's epilepsy programs advanced through Phase 2, it added five more specialists focused specifically on epilepsy and developmental encephalopathies.
That sequencing matters. The board didn't stay static as the pipeline grew from early discovery work into late-stage trials targeting drug-resistant absence seizures, developmental and epileptic encephalopathy, and Prader-Willi Syndrome.
Instead, expertise was added in step with where the science was heading, which is a meaningful signal for anyone evaluating whether a CNS drug developer's oversight structure is genuine or just decorative.
Why This Matters for Patients, Clinicians, and Investors
For patients and families dealing with conditions like drug-resistant epilepsy or Prader-Willi Syndrome, an advisory board isn't an abstract governance detail.
It affects whether a trial is designed around outcomes that matter to daily life, like seizure reduction or improved sleep, rather than outcomes that are easy to measure but clinically hollow.
For clinicians, it's a signal of whether a company understands the disease well enough to be trusted with future treatment decisions.
For investors, it's one of the clearer proxies available for assessing scientific risk in a space where the underlying biology is genuinely hard to evaluate from the outside.
FAQs
What is the difference between a scientific advisory board and a board of directors?
A board of directors oversees corporate governance, financial decisions, and executive leadership. A scientific advisory board focuses purely on the science: trial design, clinical strategy, and disease expertise. Directors have legal fiduciary duties; SAB members typically don't.
Are scientific advisory board members paid?
Most receive some combination of consulting fees, honoraria, and stock options rather than a salary. Compensation varies widely and is usually disclosed in company filings for publicly traded biotech.
How often do advisory boards meet?
It depends on the company and the stage of development. Some meet quarterly for formal reviews, while others are consulted on an as-needed basis around specific trial milestones, like an upcoming FDA meeting or a Phase 2 data readout.
Can advisory board members also be listed as clinical trial investigators?
Yes, this happens frequently in CNS drug development. A specialist advising on trial design may also run a trial site, since their clinical experience with the patient population is exactly why they were recruited to the board in the first place.
Does having a strong scientific advisory board guarantee a drug will succeed?
No. It reduces certain risks, particularly around trial design and regulatory strategy, but it doesn't change the underlying biology of whether a compound works. Plenty of well-advised programs still fail in clinical trials.
Why do CNS drug developers need more advisory input than other therapeutic areas?
Neurological and psychiatric endpoints are often more subjective and harder to standardize than, for example, tumor size in oncology. Expert input helps sort through that ambiguity, especially when defining rare disease populations like DEE or Prader-Willi Syndrome.
How can patients or families find out who sits on a company's advisory board?
Most publicly traded biotechs disclose SAB members in press releases and investor materials. For Bright Minds Biosciences, this information is available through the company's investor relations page and public filings.